Skip to main content
Erschienen in: Journal of Neurology 2/2011

01.02.2011 | Original Communication

An exploratory study of serum urate levels in patients with amyotrophic lateral sclerosis

verfasst von: Stefano Zoccolella, Isabella Laura Simone, Rosa Capozzo, Rosanna Tortelli, Antonio Leo, Eustachio D’Errico, Giancarlo Logroscino

Erschienen in: Journal of Neurology | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Urate is a natural antioxidant, and high serum urate levels could be protective against the development of amyotrophic lateral sclerosis (ALS). To determine if serum urate concentrations were lower in ALS patients than in healthy controls, we compared serum urate levels in 132 ALS patients and 337 age/sex-matched controls. Median urate levels were lower in ALS patients compared to controls (4.2mgl/dL [range:1.4–8.2], vs. 4.7 [1.7–13.1]; p = 0.04). In univariate analysis, high urate levels were less likely to be associated with ALS (odds ratio [OR]: 0.53; 95% CI: 0.29–0.97; p = 0.04), but after adjusting for age, sex and kidney function, the association was not statistically significant (OR: 0.63; 95% CI: 0.32–1.24; p = 0.18). Urate levels were lower in bulbar-onset ALS (3.9 mg/dL), compared to limb-onset ALS (4.3; p = 0.001), and in cases with longer disease duration compared to controls (4.1 mg/dL, vs. 4.7; p = 0.01). In this cross-sectional study, lower levels of serum urate were evident in ALS cases with bulbar-onset and longer disease duration, but were likely to be related to the malnutrition induced by ALS.
Literatur
1.
2.
Zurück zum Zitat Goodall EF, Morrison KE (2006) Amyotrophic lateral sclerosis (motor neuron disease): proposed mechanisms and pathways to treatment. Expert Rev Mol Med 8:1–22CrossRefPubMed Goodall EF, Morrison KE (2006) Amyotrophic lateral sclerosis (motor neuron disease): proposed mechanisms and pathways to treatment. Expert Rev Mol Med 8:1–22CrossRefPubMed
3.
Zurück zum Zitat Oda M, Satta Y, Takenaka O et al (2002) Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol Biol Evol 19:640–653PubMed Oda M, Satta Y, Takenaka O et al (2002) Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol Biol Evol 19:640–653PubMed
4.
Zurück zum Zitat Ames BN, Cathcart R, Schwiers E et al (1981) Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Nal Acad Sci USA 78:6858–6862CrossRef Ames BN, Cathcart R, Schwiers E et al (1981) Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Nal Acad Sci USA 78:6858–6862CrossRef
5.
Zurück zum Zitat Yu ZF, Bruce-Keller AJ, Goodman Y et al (1998) Uric acid protects neurons against excitotoxic and metabolic insults in cell culture, and against focal ischemic brain injury in vivo. J Neurosci Res 53:613–625CrossRefPubMed Yu ZF, Bruce-Keller AJ, Goodman Y et al (1998) Uric acid protects neurons against excitotoxic and metabolic insults in cell culture, and against focal ischemic brain injury in vivo. J Neurosci Res 53:613–625CrossRefPubMed
6.
Zurück zum Zitat Church WH, Ward VL (1994) Uric acid is reduced in the substantia nigra in Parkinson’s disease: effect on dopamine oxidation. Brain Res Bull 33:419–425CrossRefPubMed Church WH, Ward VL (1994) Uric acid is reduced in the substantia nigra in Parkinson’s disease: effect on dopamine oxidation. Brain Res Bull 33:419–425CrossRefPubMed
7.
Zurück zum Zitat Beal MF (2005) Mitochondria take center stage in aging and neurodegeneration. Ann Neurol 58:495–505CrossRefPubMed Beal MF (2005) Mitochondria take center stage in aging and neurodegeneration. Ann Neurol 58:495–505CrossRefPubMed
8.
Zurück zum Zitat Davis JW, Grandinetti A, Waslien CJ et al (1996) Observations on serum uric acid and the risk for idiopathic Parkinson’s disease. Am J Epidemiol 144:480–484PubMed Davis JW, Grandinetti A, Waslien CJ et al (1996) Observations on serum uric acid and the risk for idiopathic Parkinson’s disease. Am J Epidemiol 144:480–484PubMed
9.
Zurück zum Zitat Weisskopf MG, O’Reilly E, Chen H et al (2007) Plasma urate and risk of Parkinson’s disease. Am J Epidemiol 166:561–567CrossRefPubMed Weisskopf MG, O’Reilly E, Chen H et al (2007) Plasma urate and risk of Parkinson’s disease. Am J Epidemiol 166:561–567CrossRefPubMed
10.
Zurück zum Zitat De Vera M, Rahman MM, Rankin J et al (2008) Gout and the risk of Parkinson’s disease: a cohort study. Arthritis Rheum 59:1549–1554CrossRefPubMed De Vera M, Rahman MM, Rankin J et al (2008) Gout and the risk of Parkinson’s disease: a cohort study. Arthritis Rheum 59:1549–1554CrossRefPubMed
11.
Zurück zum Zitat de Lau LM, Koudstaal PJ, Hofman A et al (2005) Serum uric acid levels and the risk of Parkinson disease. Ann Neurol 58:797–800CrossRefPubMed de Lau LM, Koudstaal PJ, Hofman A et al (2005) Serum uric acid levels and the risk of Parkinson disease. Ann Neurol 58:797–800CrossRefPubMed
12.
Zurück zum Zitat Gao X, Chen H, Choi HK et al (2008) Diet, urate, and Parkinson’s disease risk in men. Am J Epidemiol 167:831–838CrossRefPubMed Gao X, Chen H, Choi HK et al (2008) Diet, urate, and Parkinson’s disease risk in men. Am J Epidemiol 167:831–838CrossRefPubMed
13.
Zurück zum Zitat Alonso A, Rodríguez LA, Logroscino G et al (2007) Gout and risk of Parkinson disease: a prospective study. Neurology 69:1696–1700CrossRefPubMed Alonso A, Rodríguez LA, Logroscino G et al (2007) Gout and risk of Parkinson disease: a prospective study. Neurology 69:1696–1700CrossRefPubMed
14.
Zurück zum Zitat Irizarry MC, Raman R, Schwarzschild MA et al (2009) Plasma urate and progression of mild cognitive impairment. Neurodegener Dis 6:23–28CrossRefPubMed Irizarry MC, Raman R, Schwarzschild MA et al (2009) Plasma urate and progression of mild cognitive impairment. Neurodegener Dis 6:23–28CrossRefPubMed
15.
Zurück zum Zitat Euser SM, Hofman A, Westendorp RG et al (2009) Serum uric acid and cognitive function and dementia. Brain 132:377–382CrossRefPubMed Euser SM, Hofman A, Westendorp RG et al (2009) Serum uric acid and cognitive function and dementia. Brain 132:377–382CrossRefPubMed
16.
Zurück zum Zitat Schretlen DJ, Inscore AB, Jinnah HA et al (2007) Serum uric acid and cognitive function in community-dwelling older adults. Neuropsychology 21:136–140CrossRefPubMed Schretlen DJ, Inscore AB, Jinnah HA et al (2007) Serum uric acid and cognitive function in community-dwelling older adults. Neuropsychology 21:136–140CrossRefPubMed
17.
Zurück zum Zitat Ruggiero C, Cherubini A, Miller E et al (2007) Usefulness of uric acid to predict changes in C-reactive protein and interleukin-6 in 3-year period in Italians aged 21 to 98 years. Am J Cardiol 100:115–121CrossRefPubMed Ruggiero C, Cherubini A, Miller E et al (2007) Usefulness of uric acid to predict changes in C-reactive protein and interleukin-6 in 3-year period in Italians aged 21 to 98 years. Am J Cardiol 100:115–121CrossRefPubMed
18.
Zurück zum Zitat Keizman D, Ish-Shalom M, Berliner S et al (2009) Low uric acid levels in serum of patients with ALS: further evidence for oxidative stress? J Neurol Sci 285:95–99CrossRefPubMed Keizman D, Ish-Shalom M, Berliner S et al (2009) Low uric acid levels in serum of patients with ALS: further evidence for oxidative stress? J Neurol Sci 285:95–99CrossRefPubMed
19.
Zurück zum Zitat Sohmiya M, Tanaka M, Suzuki Y et al (2005) An increase of oxidized coenzyme Q-10 occurs in the plasma of sporadic ALS patients. J Neurol Sci 228:49–53CrossRefPubMed Sohmiya M, Tanaka M, Suzuki Y et al (2005) An increase of oxidized coenzyme Q-10 occurs in the plasma of sporadic ALS patients. J Neurol Sci 228:49–53CrossRefPubMed
20.
Zurück zum Zitat Kokic AN, Stevic Z, Stojanovic S et al (2005) Biotransformation of nitric oxide in the cerebrospinal fluid of amyotrophic lateral sclerosis patients. Redox Rep 10:265–270CrossRefPubMed Kokic AN, Stevic Z, Stojanovic S et al (2005) Biotransformation of nitric oxide in the cerebrospinal fluid of amyotrophic lateral sclerosis patients. Redox Rep 10:265–270CrossRefPubMed
21.
Zurück zum Zitat Brooks BR (1994) El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial “Clinical limits of amyotrophic lateral sclerosis” workshop contributors. J Neurol Sci 124(Suppl):96–107CrossRefPubMed Brooks BR (1994) El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial “Clinical limits of amyotrophic lateral sclerosis” workshop contributors. J Neurol Sci 124(Suppl):96–107CrossRefPubMed
22.
Zurück zum Zitat Miller RG, Munsat TL, Swash M et al (1999) Consensus guidelines for the design and implementation of clinical trials in ALS. J Neurol Sci 169:2–12CrossRefPubMed Miller RG, Munsat TL, Swash M et al (1999) Consensus guidelines for the design and implementation of clinical trials in ALS. J Neurol Sci 169:2–12CrossRefPubMed
23.
Zurück zum Zitat Bos MJ, Koudstaal PJ, Hofman A et al (2006) Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke 37:1503–1507CrossRefPubMed Bos MJ, Koudstaal PJ, Hofman A et al (2006) Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke 37:1503–1507CrossRefPubMed
24.
Zurück zum Zitat Brooks BR (2003) Functional scales: summary. Amyotroph Lateral Scler Other Motor Neuron Disord 3(suppl1):S13–S18 Brooks BR (2003) Functional scales: summary. Amyotroph Lateral Scler Other Motor Neuron Disord 3(suppl1):S13–S18
25.
Zurück zum Zitat Kimura F, Fujimura C, Ishida S et al (2006) Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology 66:265–267CrossRefPubMed Kimura F, Fujimura C, Ishida S et al (2006) Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology 66:265–267CrossRefPubMed
26.
Zurück zum Zitat Levey AS, Coresh J, Greene T et al (2007) Chronic kidney disease epidemiology collaboration. expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 53:766–772CrossRefPubMed Levey AS, Coresh J, Greene T et al (2007) Chronic kidney disease epidemiology collaboration. expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 53:766–772CrossRefPubMed
27.
Zurück zum Zitat Reynolds A, Laurie C, Lee Mosley R et al (2007) Oxidative stress and the pathogenesis of neurodegenerative disorders. Intern Rev Neurobiol 82:297–325CrossRef Reynolds A, Laurie C, Lee Mosley R et al (2007) Oxidative stress and the pathogenesis of neurodegenerative disorders. Intern Rev Neurobiol 82:297–325CrossRef
28.
Zurück zum Zitat Hervias I, Beal MF, Manfredi G (2006) Mitochondrial dysfunction and amyotrophic lateral sclerosis. Muscle Nerve 33:598–608CrossRefPubMed Hervias I, Beal MF, Manfredi G (2006) Mitochondrial dysfunction and amyotrophic lateral sclerosis. Muscle Nerve 33:598–608CrossRefPubMed
29.
Zurück zum Zitat Pacher P, Beckman KS, Liaudet L (2007) Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87:315–424CrossRefPubMed Pacher P, Beckman KS, Liaudet L (2007) Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87:315–424CrossRefPubMed
30.
Zurück zum Zitat Tohgi H, Abe T, Yamazaki K et al (1999) Increase in oxidized NO products and reduction in oxidized glutathione in cerebrospinal fluid from patients with sporadic form of amyotrophic lateral sclerosis. Neurosci Lett 260:204–206CrossRefPubMed Tohgi H, Abe T, Yamazaki K et al (1999) Increase in oxidized NO products and reduction in oxidized glutathione in cerebrospinal fluid from patients with sporadic form of amyotrophic lateral sclerosis. Neurosci Lett 260:204–206CrossRefPubMed
31.
Zurück zum Zitat Du Y, Chen CP, Tseng CY et al (2007) Astroglia-mediated effects of uric acid to protect spinal cord neurons from glutamate toxicity. Glia 55:463–472CrossRefPubMed Du Y, Chen CP, Tseng CY et al (2007) Astroglia-mediated effects of uric acid to protect spinal cord neurons from glutamate toxicity. Glia 55:463–472CrossRefPubMed
32.
Zurück zum Zitat Ruggiero C, Cherubini A, Lauretani F et al (2009) Uric acid and dementia in community-dwelling older persons. Dement Geriatr Cogn Disord 27:382–389CrossRefPubMed Ruggiero C, Cherubini A, Lauretani F et al (2009) Uric acid and dementia in community-dwelling older persons. Dement Geriatr Cogn Disord 27:382–389CrossRefPubMed
33.
Zurück zum Zitat Schiess M, Oh I (2008) Serum uric acid and clinical progression in Parkinson disease. Potential biomarker for nigrostriatal failure. Arch Neurol 65:698–699CrossRefPubMed Schiess M, Oh I (2008) Serum uric acid and clinical progression in Parkinson disease. Potential biomarker for nigrostriatal failure. Arch Neurol 65:698–699CrossRefPubMed
34.
Zurück zum Zitat Ruggiero C, Cherubini A, Ble A et al (2006) Uric acid and inflammatory markers. Eur Heart J 27:1174–1181CrossRefPubMed Ruggiero C, Cherubini A, Ble A et al (2006) Uric acid and inflammatory markers. Eur Heart J 27:1174–1181CrossRefPubMed
35.
Zurück zum Zitat Shi Y, Evans JE, Rock KL (2003) Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425:516–521CrossRefPubMed Shi Y, Evans JE, Rock KL (2003) Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425:516–521CrossRefPubMed
36.
Zurück zum Zitat Hayden MR, Tyagi SC (2004) Uric acid: a new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: the urate redox shuttle. Nutr Metab (Lond) 1(1):10CrossRef Hayden MR, Tyagi SC (2004) Uric acid: a new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: the urate redox shuttle. Nutr Metab (Lond) 1(1):10CrossRef
37.
Zurück zum Zitat Gasteyger C, Suter M, Calmes JM et al (2006) Changes in body composition, metabolic profile and nutritional status 24 months after gastric banding. Obes Surg 16:243–250CrossRefPubMed Gasteyger C, Suter M, Calmes JM et al (2006) Changes in body composition, metabolic profile and nutritional status 24 months after gastric banding. Obes Surg 16:243–250CrossRefPubMed
38.
Zurück zum Zitat Traynor BJ, Bruijn L, Conwit R et al (2006) Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology 67:20–27CrossRefPubMed Traynor BJ, Bruijn L, Conwit R et al (2006) Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology 67:20–27CrossRefPubMed
Metadaten
Titel
An exploratory study of serum urate levels in patients with amyotrophic lateral sclerosis
verfasst von
Stefano Zoccolella
Isabella Laura Simone
Rosa Capozzo
Rosanna Tortelli
Antonio Leo
Eustachio D’Errico
Giancarlo Logroscino
Publikationsdatum
01.02.2011
Verlag
Springer-Verlag
Erschienen in
Journal of Neurology / Ausgabe 2/2011
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-010-5735-9

Weitere Artikel der Ausgabe 2/2011

Journal of Neurology 2/2011 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Neu im Fachgebiet Neurologie

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.